Please Wait.....
Report
Global Antiviral Drugs Market Report and Forecast 2023-2031
Market Report I 2023-04-24 I 147 Pages I EMR Inc.
Global Antiviral Drugs Market Report and Forecast 2023-2031
Global Antiviral Drugs Market Outlook
The global antiviral drugs market size attained a value of USD 53.0 billion in 2022. The market is anticipated to grow at a CAGR of 4.1% during the forecast period of 2023-2031 to attain a value of USD 76.3 billion by 2031.
Antiviral Drugs Market: Introduction
Antiviral drugs are a class of medications used to treat viral infections by inhibiting the growth and replication of viruses. Unlike antibiotics, which target bacteria, antiviral drugs specifically target viral pathogens. These drugs are designed to interfere with the viral life cycle or the virus's ability to infect host cells, thereby preventing the virus from causing illness or limiting the severity of the disease.
Antiviral drugs are used for a wide range of viral infections, including:
1. Influenza: Antiviral drugs such as oseltamivir (Tamiflu), zanamivir (Relenza), and baloxavir (Xofluza) are used to treat and prevent influenza (flu) infections. These drugs can help reduce the severity and duration of flu symptoms when taken within 48 hours of symptom onset.
2. Human Immunodeficiency Virus (HIV): Antiretroviral drugs, including nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), and entry inhibitors, are used in combination therapy to manage HIV infection and slow the progression to Acquired Immunodeficiency Syndrome (AIDS).
3. Hepatitis B and C: Antiviral drugs such as entecavir, tenofovir, and lamivudine are used to treat chronic hepatitis B, while direct-acting antiviral agents (DAAs) such as sofosbuvir, ledipasvir, and daclatasvir are used to treat hepatitis C. These drugs help suppress viral replication and prevent liver damage.
4. Herpes viruses: Antiviral drugs like acyclovir, valacyclovir, and famciclovir are used to treat infections caused by herpes viruses, including genital herpes, cold sores, and shingles. These drugs help reduce the severity and duration of symptoms and can also be used as suppressive therapy to prevent recurrent outbreaks.
5. Respiratory Syncytial Virus (RSV): Ribavirin is an antiviral drug used to treat severe RSV infections in high-risk patients, such as infants, young children, and immunocompromised individuals.
6. Cytomegalovirus (CMV): Antiviral drugs such as ganciclovir, valganciclovir, and foscarnet are used to treat CMV infections, particularly in immunocompromised patients, including organ transplant recipients and individuals with HIV/AIDS.
Antiviral drugs are crucial in the management of viral infections, particularly for high-risk populations, and can help reduce the morbidity and mortality associated with these infections. However, the development of antiviral resistance and the limited spectrum of action for certain antiviral drugs remain ongoing challenges in the field of antiviral therapy.
Antiviral Drugs Market- Introduction
Antiviral Drugs Market Segmentations
The market can be categorised into drug class, type, application, dosage form, end user, distribution channel, and region.
Market Breakup by Drug Class
- DNA Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Neuraminidase Inhibitors
- Others
Market Breakup by Type
- Branded
- Generics
Market Breakup by Application
- HIV
- Hepatitis
- Influenza
- Herpes
- Others
Market Breakup by Dosage Form
- Market Overview
- Oral
- Topical
- Parenteral
Market Breakup by End user
- Hospitals
- Homecare
- Specialty Clinics
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Antiviral Drugs Market Scenario
The global antiviral drugs market is witnessing substantial growth due to the increasing prevalence of viral infections, such as HIV/AIDS, hepatitis B and C, influenza, herpes, and the recent COVID-19 pandemic. Antiviral drugs are crucial in the management and prevention of viral infections and play a vital role in reducing morbidity and mortality associated with these diseases. The market encompasses a wide range of products, including nucleoside analogues, protease inhibitors, reverse transcriptase inhibitors, and neuraminidase inhibitors, among others.
Market Drivers
Several factors contribute to the growth of the antiviral drugs market. The rising global burden of viral infections, coupled with an increasing awareness of preventive measures and the importance of early treatment, is driving the demand for antiviral drugs. Additionally, advancements in drug discovery and development, along with a focus on personalized medicine and targeted therapies, are propelling the market forward. Moreover, government initiatives to improve access to healthcare and antiviral treatments, as well as increased funding for research and development, contribute to market expansion.
Market Challenges
Despite the promising growth, the antiviral drugs market faces certain challenges. The emergence of drug-resistant viral strains can limit the effectiveness of existing antiviral drugs, necessitating the development of new and more potent therapies. Additionally, the high cost of drug development and stringent regulatory requirements may hinder the introduction of new products to the market. Moreover, the limited spectrum of action for certain antiviral drugs and the need for more effective and safer treatment options remain ongoing challenges in the field of antiviral therapy.
Regional Analysis
Geographically, the global antiviral drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominates the market due to its advanced healthcare infrastructure, high awareness about viral diseases, and the presence of key market players. Europe follows closely, with Asia-Pacific anticipated to be the fastest-growing region, owing to the increasing prevalence of viral infections, growing healthcare expenditure, and improving healthcare infrastructure.
Future Outlook
The antiviral drugs market is expected to witness sustained growth in the coming years, primarily driven by the increasing prevalence of viral infections and the development of novel therapeutics. The advent of new technologies, such as gene editing and nanotechnology, may lead to the development of innovative antiviral therapies with improved efficacy and safety profiles. Additionally, emerging markets in the Asia-Pacific region present significant growth opportunities for the market
Key Players in the Global Antiviral Drugs Market
The report gives an in-depth analysis of the key players involved in the antiviral drugs market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Gilead Sciences, Inc.
- F. Hoffmann-La Roche AG
- GlaxoSmithKline plc.
- AbbVie Inc.
- Merck and Co., Inc.
- Johnson and Johnson Services, Inc.
- Cipla Inc.
- Bristol-Myers Squibb Company
- Aurobindo Pharma Limited
- Dr. Reddy's Laboratories Ltd.
- Laurus Labs
- Amneal Pharmaceuticals
- Zydus Group
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Viral Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Viral Diseases Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Viral Disease Epidemiology (2016-2031)
5.3 Europe Viral Disease Epidemiology (2016-2031)
5.4 Asia-Pacific Viral Disease Epidemiology (2016-2031)
5.5 Latin America Viral Disease Epidemiology (2016-2031)
5.6 Middle East & Africa Viral Disease Epidemiology (2016-2031)
6 Global Antiviral Drugs Market Overview
6.1 Global Antiviral Drugs Market Historical Value (2016-2022)
6.2 Global Antiviral Drugs Market Forecast Value (2023-2031)
7 Global Antiviral Drugs Market Landscape
7.1 Antiviral Drugs: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Antiviral Drugs: Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Type
7.2.3 Analysis by Application
7.2.4 Analysis by Dosage Form
7.2.5 Analysis by End User
7.2.6 Analysis by Distribution Channel
8 Global Antiviral Drugs Market Dynamics
8.1 Market Drivers and Constraints
8.2 SWOT Analysis
8.3 Porter's Five Forces Model
8.4 Key Demand Indicators
8.5 Key Price Indicators
8.6 Industry Events, Initiatives, and Trends
8.7 Value Chain Analysis
9 Global Antiviral Drugs Market Segmentation
9.1 Global Antiviral Drugs Market by Drug Class
9.1.1 Market Overview
9.1.2 DNA Polymerase Inhibitors
9.1.3 Reverse Transcriptase Inhibitors
9.1.4 Protease Inhibitors
9.1.5 Neuraminidase Inhibitors
9.1.6 Others
9.2 Global Antiviral Drugs Market by Type
9.2.1 Market Overview
9.2.2 Branded
9.2.3 Generics
9.3 Global Antiviral Drugs Market by Application
9.3.1 Market Overview
9.3.2 HIV
9.3.3 Hepatitis
9.3.4 Influenza
9.3.5 Herpes
9.3.6 Others
9.4 Global Antiviral Drugs Market by Dosage Form
9.4.1 Market Overview
9.4.2 Oral
9.4.3 Topical
9.4.4 Parenteral
9.5 Global Antiviral Drugs Market by End User
9.5.1 Market Overview
9.5.2 Hospitals
9.5.3 Homecare
9.5.4 Specialty Clinics
9.5.5 Others
9.6 Global Antiviral Drugs Market by Distribution Channel
9.6.1 Market Overview
9.6.2 Hospital Pharmacy
9.6.3 Retail Pharmacy
9.6.4 Online Pharmacy
9.7 Global Antiviral Drugs Market by Region
9.7.1 Market Overview
9.7.2 North America
9.7.3 Europe
9.7.4 Asia Pacific
9.7.5 Latin America
9.7.6 Middle East and Africa
10 North America Antiviral Drugs Market
10.1 Market Share by Country
10.2 United States of America
10.3 Canada
11 Europe Antiviral Drugs Market
11.1 Market Share by Country
11.2 United Kingdom
11.3 Germany
11.4 France
11.5 Italy
11.6 Others
12 Asia Pacific Antiviral Drugs Market
12.1 Market Share by Country
12.2 China
12.3 Japan
12.4 India
12.5 ASEAN
12.6 Australia
12.7 Others
13 Latin America Antiviral Drugs Market
13.1 Market Share by Country
13.2 Brazil
13.3 Argentina
13.4 Mexico
13.5 Others
14 Middle East and Africa Antiviral Drugs Market
14.1 Market Share by Country
14.2 Saudi Arabia
14.3 United Arab Emirates
14.4 Nigeria
14.5 South Africa
14.6 Others
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
15.1.5 Others
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Gilead Sciences, Inc.
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 F. Hoffmann-La Roche AG
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 GlaxoSmithKline plc.
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 AbbVie Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Merck and Co., Inc.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Johnson and Johnson Services, Inc.
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Cipla Inc.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Bristol-Myers Squibb Company
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Aurobindo Pharma Limited
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Dr. Reddy's Laboratories Ltd.
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Laurus Labs
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Amneal Pharmaceuticals
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Zydus Group
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
22 Antiviral Drugs - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security